Downstream Cost Savings, Will Encourage EU5 Payers to Think Beyond the Price Tag, Although Drug Cost Must Be Well Balanced Against Potential Uptake, According to a New Report from Decision Resources
BURLINGTON, Mass., March 18, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite its recent market entry, Johnson & Johnson/Janssen Biotech/Janssen Cilag's Zytiga has heavily penetrated surveyed EU5 (France, Germany, Italy, Spain and the United Kingdom) oncologists' second-line treatment of metastatic castrate-resistant prostate cancer (mCRPC) patients who have received prior treatment with docetaxel. Uptake of Zytiga is especially high in France and the United Kingdom, where, on average, approximately half of respondents' second-line patients are prescribed Zytiga.
Among respondents in most countries, Sanofi's Jevtana is more commonly used in the third-line than the second-line setting, suggesting that second-to-market Zytiga is displacing Jevtana to later-line mCRPC. In support of this finding, most of those surveyed in all countries indicate that the recent launch of Zytiga will influence a shift in prescribing of Jevtana toward later-line mCRPC treatment in the next 12 months.
The new European Physician & Payer Forum report entitled The Dynamic Prostate Cancer Landscape: How Will European Payer and Prescriber Attitudes Shape This Competitive Market? finds that more than one-third of respondents in Germany and Spain believe Zytiga's launch will significantly influence a shift in Jevtana's prescribing, while almost one-quarter of those in Italy agree. Zytiga's more favorable side-effect profile, convenient oral administration, and mechanism of action likely explain why such a substantial percentage of physicians expect this trend. At the end of 2015, despite the anticipated approval of three new therapies—Medivation/Astellas Pharma's Xtandi, Algeta/Bayer HealthCare's radium-223, and Takeda/Millennium's orteronel—Zytiga will maintain its position as the favored second-line mCRPC therapy among surveyed EU5 physicians.
This report also finds that, in addition to robust efficacy, therapeutic innovation and demonstrable downstream cost savings are key market access levers that will encourage EU5 payers to think beyond an emerging agent's proposed price tag. Pharmaceutical innovation is key to reimbursement decision making in Italy and Spain, and, in the former, inclusion on AIFA's innovative drugs list ensures funding across regions.
"Savings in hospitalization and supportive care costs, as well as the societal benefits of improving quality of life, will help encourage uptake within countries following admission to reimbursement," said Decision Resources Senior Director Rachel Webster, Ph.D. "Costs associated with management of Jevtana's side effects may well have contributed to NICE's decision on its lack of cost-effectiveness. Furthermore, the United Kingdom's value-based pricing system, set to be implemented at the end of this year, will pave the way for consideration of wider societal benefits and associated cost savings, and the principles of this concept are increasingly evident across the EU5."
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
SOURCE Decision Resources